CN111432883B - 新型烟碱结合抗体 - Google Patents

新型烟碱结合抗体 Download PDF

Info

Publication number
CN111432883B
CN111432883B CN201880067101.7A CN201880067101A CN111432883B CN 111432883 B CN111432883 B CN 111432883B CN 201880067101 A CN201880067101 A CN 201880067101A CN 111432883 B CN111432883 B CN 111432883B
Authority
CN
China
Prior art keywords
ser
val
thr
leu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880067101.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111432883A (zh
Inventor
马修·W·卡尼克
托马斯·齐斯泰兹
尼古拉·布里特瑞米恩里
斯蒂芬妮·法莱特
祖扎那·宾索瓦
斯蒂文·富勒
马克·G·勒赛格
保罗·本特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brinker Biomedical Simple Stock Co
Hennepin Institute Of Health Care
Antidote Therapeutics Inc
Original Assignee
Brinker Biomedical Simple Stock Co
Hennepin Institute Of Health Care
Antidote Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brinker Biomedical Simple Stock Co, Hennepin Institute Of Health Care, Antidote Therapeutics Inc filed Critical Brinker Biomedical Simple Stock Co
Publication of CN111432883A publication Critical patent/CN111432883A/zh
Application granted granted Critical
Publication of CN111432883B publication Critical patent/CN111432883B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880067101.7A 2017-08-15 2018-08-14 新型烟碱结合抗体 Active CN111432883B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545696P 2017-08-15 2017-08-15
US62/545,696 2017-08-15
PCT/US2018/046621 WO2019036419A1 (en) 2017-08-15 2018-08-14 NEW NICOTINE BINDING ANTIBODIES

Publications (2)

Publication Number Publication Date
CN111432883A CN111432883A (zh) 2020-07-17
CN111432883B true CN111432883B (zh) 2024-10-01

Family

ID=63405495

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880067101.7A Active CN111432883B (zh) 2017-08-15 2018-08-14 新型烟碱结合抗体

Country Status (11)

Country Link
US (2) US11440970B2 (https=)
EP (2) EP4624496A3 (https=)
JP (1) JP7364555B2 (https=)
KR (1) KR102712005B1 (https=)
CN (1) CN111432883B (https=)
AU (1) AU2018317372B2 (https=)
BR (1) BR112020002994A2 (https=)
CA (1) CA3072767A1 (https=)
ES (1) ES3041362T3 (https=)
MX (1) MX2020001725A (https=)
WO (1) WO2019036419A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801594A1 (en) * 2018-06-06 2021-04-14 Antidote Therapeutics, Inc. Methods for improving circulation and treating cardiovascular disease
KR102530111B1 (ko) * 2022-03-11 2023-05-10 앱클론(주) 코티닌을 표적하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이들의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101355967A (zh) * 2005-11-15 2009-01-28 范因斯坦医学研究院 用α-7烟碱受体抗体治疗炎性疾病
CN101878228A (zh) * 2007-11-29 2010-11-03 赛托斯生物技术公司 尼古丁特异性人单克隆抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194158A3 (en) * 1985-03-08 1988-02-24 Baylor College of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002058635A2 (en) 2001-01-26 2002-08-01 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
US20050089524A1 (en) 2002-03-01 2005-04-28 Sanderson Sam D. Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20060111271A1 (en) 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
EP1963308A4 (en) 2005-11-28 2010-12-15 Nabi Biopharmaceuticals METHOD FOR PRODUCING A NICOTINE HAPTEN
WO2007100755A1 (en) 2006-02-27 2007-09-07 Nabi Biopharmaceuticals Method for decreasing the toxic effects of nicotine on fetuses in pregnant women
EP2065398A1 (en) 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
JP2011524521A (ja) 2008-06-13 2011-09-01 ナビ バイオファーマシューティカルズ 喫煙停止キットおよび方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101355967A (zh) * 2005-11-15 2009-01-28 范因斯坦医学研究院 用α-7烟碱受体抗体治疗炎性疾病
CN101878228A (zh) * 2007-11-29 2010-11-03 赛托斯生物技术公司 尼古丁特异性人单克隆抗体

Also Published As

Publication number Publication date
KR20200089255A (ko) 2020-07-24
WO2019036419A1 (en) 2019-02-21
EP3668598A1 (en) 2020-06-24
EP3668598B1 (en) 2025-07-30
US20230089068A1 (en) 2023-03-23
AU2018317372A1 (en) 2020-03-05
US11440970B2 (en) 2022-09-13
ES3041362T3 (en) 2025-11-11
EP4624496A3 (en) 2025-12-17
US20200377616A1 (en) 2020-12-03
AU2018317372B2 (en) 2025-06-26
BR112020002994A2 (pt) 2020-08-11
MX2020001725A (es) 2020-08-20
KR102712005B1 (ko) 2024-09-30
JP2020531480A (ja) 2020-11-05
CA3072767A1 (en) 2019-02-21
JP7364555B2 (ja) 2023-10-18
CN111432883A (zh) 2020-07-17
EP4624496A2 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
CN113474369B (zh) 转铁蛋白受体结合分子、其偶联物和它们的用途
Flinspach et al. Insensitivity to pain induced by a potent selective closed-state Nav1. 7 inhibitor
TWI335336B (https=)
De Villiers et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell
Journigan et al. TRPM8 ion channel ligands for new therapeutic applications and as probes to study menthol pharmacology
BR112014003679B1 (pt) Domínio variável de imunoglobulina único, composição farmacêutica, formulação, ácido nucleico isolado ou recombinante, vetor, microorganismo transgênico, e, uso de uma composição farmacêutica
CN101668773A (zh) 人工程化抗b因子抗体
JP2023134636A (ja) 神経変性および炎症性疾患の治療に使用するためのｃｄ３８と特異的に結合する化合物
RS65360B1 (sr) Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
KR20220133234A (ko) 항-tslp 항체를 이용한 염증성 또는 폐쇄성 기도 질환의 치료 방법
US20230089068A1 (en) Novel nicotine-binding antibodies
KR101947758B1 (ko) 포스포릴콜린에 대한 신규 항체
Raleigh et al. Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies
CN115698059A (zh) 使用抗bet v 1抗体治疗过敏的方法
Pentel et al. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats
CN114423454A (zh) 抗类胰蛋白酶抗体的给药
US20220267474A1 (en) Methods for improving circulation and treating cardiovascular disease
CN116096746A (zh) 多瘤病毒中和抗体的给药
TW202417054A (zh) 配體－細胞毒性藥物偶聯物及其藥物用途
WO2026062582A1 (en) Methods of treatment using anti-trem2 antibodies
HK40067775A (en) Dosing for anti-tryptase antibodies
KR20260057440A (ko) 항-cd203c 항체 접합체 및 이의 용도
JP2025523822A (ja) イブジラストの注射用製剤
Jahan Part I: Design and Synthesis of Novel Drugs to Treat Asthma By Targeting GABAA Receptors in the Lung Part II: Design and Synthesis of Novel Α2/α3 Subtype Selective GABAAR Ligands for CNS Disorders
Jahan Part I Design and Synthesis of Novel Drugs to Treat Asthma by Targeting GABAA Receptors in the Lung Part II Design and Synthesis of Novel a2/a3 Subtype Selective Gabaar Ligands for CNS Disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant